Methadon Hcl Tiofarma

Methadone Hydrochloride, the active ingredient in Methadon Hcl Tiofarma, is a synthetic opioid presented as an oral tablet for oral use. It is used to manage opioid dependence and chronic pain in adults.

GNH USA supplies Methadon Hcl Tiofarma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone Hydrochloride is employed in the management of opioid‑related conditions and chronic pain.

- Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe persistent pain. - Opioid detoxification: facilitates gradual tapering of opioid use under medical supervision.

Methadone Hydrochloride may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Constipation: reduced bowel motility. - Drowsiness: increased sedation. - Sweating: excessive perspiration.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Cardiac arrhythmia: abnormal heart rhythm, including QT prolongation. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Methadone Hydrochloride, clinicians should consider several safety precautions. - Assess cardiac risk: evaluate QT interval and electrolyte status before initiation. - Monitor for dependence: watch for signs of misuse or addiction during therapy. - Adjust in hepatic impairment: consider dose reduction in patients with liver dysfunction. - Caution in respiratory disorders: avoid use in severe asthma or COPD without close monitoring. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Methadone Hydrochloride can interact with other medicines, affecting its concentration or the effect of co‑administered drugs.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may cause dangerous accumulation. - CNS depressants (e.g., benzodiazepines, alcohol): increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce methadone levels. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): may enhance cardiac risk.